346 related articles for article (PubMed ID: 26598548)
1. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
7. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.
Locati LD; Galbiati D; Calareso G; Alfieri S; Singer S; Cavalieri S; Bergamini C; Bossi P; Orlandi E; Resteghini C; Platini F; Granata R; Quattrone P; Mancinelli M; Mariani L; Lo Vullo S; Licitra LF
Cancer; 2020 Jan; 126(9):1888-1894. PubMed ID: 32031693
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
Pfeffer MR; Talmi Y; Catane R; Symon Z; Yosepovitch A; Levitt M
Oral Oncol; 2007 Jan; 43(1):33-6. PubMed ID: 16757202
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
Goncalves PH; Heilbrun LK; Barrett MT; Kummar S; Hansen AR; Siu LL; Piekarz RL; Sukari AW; Chao J; Pilat MJ; Smith DW; Casetta L; Boerner SA; Chen A; Lenkiewicz E; Malasi S; LoRusso PM
Oncotarget; 2017 May; 8(20):32918-32929. PubMed ID: 28415633
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
Thomson DJ; Silva P; Denton K; Bonington S; Mak SK; Swindell R; Homer J; Sykes AJ; Lee LW; Yap BK; Slevin NJ
Head Neck; 2015 Feb; 37(2):182-7. PubMed ID: 24346857
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
Rodriguez CP; Martins RG; Baik C; Chow LQ; Santana-Davila R; Goulart BH; Lee S; Eaton KD
Head Neck; 2018 Mar; 40(3):584-589. PubMed ID: 29283469
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
Hoover AC; Milhem MM; Anderson CM; Sun W; Smith BJ; Hoffman HT; Buatti JM
Head Neck; 2015 May; 37(5):722-6. PubMed ID: 24596143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
